Branson notes Relenza was designed using early computational drug discovery methods
Kim Branson · AI in Pharmaceutical R&D with Kim Branson · Aug 1, 2024 · at 1:54
Kim Branson, SVP and Global Head of AI and Machine Learning at GSK, discusses early pioneers in computational biology who designed the influenza drug Relenza.
0:00 / 0:28exact quote · 28.8s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“So, so, I was working with Joseph Aghese and Peter Coleman and Brian Smith, and these are the people behind the first neuro-interdates drive, which actually was designed actually with computation. So, they used a program called Goodford This grid to map the protein surface and work out to put this functional group there, and, you know, it was all based off the original sugar molecule, but it was actually designed using a computational method. They were believers in it, because they had built something, and it became marketed as Relenza, I think by GSK, ironically where I am now, so yeah.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Kim Branson
Branson warns biological models showing 0.9 accuracy usually contain underlying errors
“In biology, as you know, like, the best model you can build has, like, a figure of merit of accuracy, like.6, if it's .9, anything that looks great, there's something wrong.”
Branson predicts every drug launched by GSK will have accompanying software
“So every, every software, every drug VSK will launch will have software that sits around it. I think that's gonna be true of everybody, and there's, we're going to see, there's software that will sit around every drug, and we'll say, you know, who should use i…”
GSK's active learning target discovery is 20% faster than random screening
“That's about 20% faster we've shown than doing a random screen.”
Branson notes simple ML models yield most gains over complex ones
“Basically the simple stuff gets you there, and for the extra five percent gained, you need all the extra complexity. I think that is still true now.”
Branson calls human outcome data big pharma's biggest competitive AI advantage
“Outcome data is, is, is the gold standard data to have, right? It's the rarest data that's really, like, one of the advantages of pharmaceutical companies have, because they can generate data in humans at scale in a safe, ethical manner.”
GSK made AI core to its strategy via in-house functional genomics
“They're fully investing in the things I thought were very important at the time, which was, you know, these large genetic databases coming online and functional genomics. So he was way ahead in the, in sort of the thinking about CRISPR and like the gene pertur…”